已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study

扎那米韦 医学 奥司他韦 神经氨酸酶抑制剂 优势比 置信区间 神经氨酸酶 传输(电信) 入射(几何) 逻辑回归 内科学 病毒学 病毒 工程类 传染病(医学专业) 物理 疾病 光学 电气工程 2019年冠状病毒病(COVID-19)
作者
Takuji Komeda,Takahiro Takazono,Naoki Hosogaya,Eriko Ogura,Masakazu Fujiwara,Hideyuki Miyauchi,Yoshikazu Ajisawa,Shimpei Iwata,Hideaki Watanabe,Keiichi Honda,Yoshitake Kitanishi,Kanae Hara,Hiroshi Mukae
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:72 (11): e859-e867 被引量:14
标识
DOI:10.1093/cid/ciaa1622
摘要

Abstract Background Baloxavir marboxil (baloxavir) is expected to reduce influenza transmission by rapid reduction of viral load. The incidence of household transmission was compared between index patients (IPs) treated with baloxavir and those treated with neuraminidase inhibitors. Methods Using a Japanese claims database, the first family members with influenza diagnosis during the 2018–2019 influenza season were identified as IPs, and the diagnosis date was designated day 1. According to the anti-influenza drug dispensed to the IP, their families were classified into the oral baloxavir group and 3 controls: oral oseltamivir group (a primary control), inhaled zanamivir group, and inhaled laninamivir group. A household transmission was defined as influenza diagnosed for any non-IP family members during days 3−8. The incidence of household transmission was compared between groups using a logistic regression model adjusting backgrounds of IPs. Results The proportion of families with household transmission was 17.98% (15 226 of 84 672) in the baloxavir group and 24.16% (14 983 of 62 004) in the oseltamivir group. The covariate-adjusted odds ratio (oseltamivir/baloxavir) was 1.09 (95% confidence interval [95% CI], 1.05–1.12), which indicated significantly lower incidence in the baloxavir group. The adjusted odds ratios (controls/baloxavir) against zanamivir and laninamivir were 0.93 (95% CI, .89–.97) and 0.99 (95% CI, .96–1.02), respectively. Conclusions Baloxavir may contribute to reduction in household transmission compared with oseltamivir. In comparison between baloxavir and inhalants, a similar reduction was not shown and it might be due to unmeasured confounding by administration route differences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aero完成签到 ,获得积分10
1秒前
1秒前
hyr发布了新的文献求助10
1秒前
tingting发布了新的文献求助10
4秒前
稳重的紫易完成签到,获得积分20
4秒前
5秒前
eye发布了新的文献求助10
5秒前
科研通AI2S应助方块块采纳,获得10
7秒前
向日葵完成签到,获得积分10
9秒前
10秒前
十三号失眠完成签到 ,获得积分10
10秒前
林蓥颖完成签到,获得积分10
11秒前
iNk应助科研通管家采纳,获得20
11秒前
斯文败类应助科研通管家采纳,获得10
11秒前
科研通AI5应助科研通管家采纳,获得10
11秒前
情怀应助科研通管家采纳,获得10
12秒前
iNk应助科研通管家采纳,获得20
12秒前
Ava应助科研通管家采纳,获得50
12秒前
12秒前
12秒前
13秒前
16秒前
17秒前
余子健发布了新的文献求助10
18秒前
柠檬水发布了新的文献求助10
18秒前
554802336应助hyr采纳,获得30
20秒前
斯文败类应助tingting采纳,获得10
23秒前
peiter发布了新的文献求助10
23秒前
标致大开完成签到 ,获得积分10
25秒前
huangy发布了新的文献求助10
26秒前
我是老大应助Lucille采纳,获得10
26秒前
LSQ完成签到 ,获得积分10
26秒前
30秒前
U9A驳回了554802336应助
31秒前
32秒前
32秒前
33秒前
34秒前
konosuba完成签到,获得积分0
35秒前
积极的蘑菇完成签到 ,获得积分10
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976531
求助须知:如何正确求助?哪些是违规求助? 3520603
关于积分的说明 11204100
捐赠科研通 3257210
什么是DOI,文献DOI怎么找? 1798648
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806570